Trial · NCT04697810
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
NCT04697810, Phase 2, Unknown, Can-Fite BioPharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH). Trials, record NCT04697810. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04697810
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
- NCT number
- NCT04697810
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 114 participants, estimated
- Lead sponsor
- Can-Fite BioPharma
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Namodenoson, Placebo
- First posted
- 2021-01-06
- Last updated
- 2024-07-31
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Non-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS) | 36 weeks | Proportion of subjects who achieve a ≥2-point improvement in the non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASH CRN) |
| Primary | Adverse events (AEs) | 36 weeks | Incidence of AEs |
| Secondary | Alanine transaminase (ALT) mean | 36 weeks | Mean percent change from Baseline in serum ALT level |
| Secondary | Steady-state blood level of namodenoson | 36 weeks | Plasma trough concentration (ng/mL) of namodenoson taken at pre-dose samples |
| Other | ALT absolute | 36 weeks | Absolute change from Baseline in serum ALT |
| Other | ALT threshold | 36 weeks | Proportion of subjects who achieve ≥17-point reduction from Baseline in serum ALT |
| Other | Weight | 36 weeks | Change from Baseline in body weight |
| Other | Adiponectin | 36 weeks | Change from Baseline in serum adiponectin level |
| Other | Released N-terminal pro-peptide of type III collagen neoepitope (Pro-C3) | 36 weeks | Change from Baseline in Pro-C3 |
| Other | Serum Enhanced Liver Fibrosis (ELF) Score | 36 weeks | Change from Baseline in ELF Score, which is a continuous scale starting at zero, with higher scores indicating more severe disease |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04697810
GET https://conductscience.org/api/trials/v1/NCT04697810/registered